Business Wire

MA-PERKINELMER

20.4.2020 15:02:08 CEST | Business Wire | Press release

Share
PerkinElmer Launches Solutions to Streamline Analysis for Labs in Pharmaceuticals, Semiconductors, Biomonitoring, Food and Materials

PerkinElmer, Inc. , a global leader committed to innovating for a healthier world, today expanded its analysis and automation portfolio for quality, safety and content testing. Geared for pharmaceutical, semiconductor, biomonitoring, food, materials and academia labs, the new offerings will help streamline workflows, sharpen insights and performance and provide ease of use. They include:

NexION® 5000 Multi-Quadruple ICP-MS – for demanding trace element analyses, this solution drives accurate and repeatable results and helps future-proof labs. Leveraging new and proprietary technologies, it is the first in its category to offer four quadrupoles – meeting and exceeding rigorous trace-elemental testing requirements for labs working in areas like semiconductor R&D and device manufacturing as well as biomonitoring. The new offering goes beyond current triple-quad ICP-MS performance to deliver exceptionally low background equivalent concentrations (BECs) of <1 ppt even in hot plasma and outstanding detection limits in a matrix-tolerant, low-maintenance solution.

Spectrum™ 3 spectrometer – a tri-range FT-IR spectroscopy solution featuring 100 scans/second for pharmaceutical, polymer, materials, food, academic or chemical labs doing advanced research, product development or reaction monitoring. Working across solid, liquid or gas samples and including options for near, mid and far-IR ranges in one instrument, it brings strong flexibility. It is also suitable for users of varying skill levels as it is the first FT-IR platform to offer a fully integrated TG-IR hyphenation (EGA4000) solution.

For more advanced applications, the offering can be easily hyphenated with PerkinElmer’s TGA™ 8000 thermogravimetric analyzer and Clarus® SQ8 GC/MS chromatography system. Spectrum 3 also leverages PerkinElmer’s Spectrum™ 10 software (including integrated time resolved software and CFR 21 Part 11 compliance options) and cloud connectivity via NetPlus™ software – delivering accurate results, integrated workflows and global, real-time collaboration.

Spectrum™ Two + spectrometer - a powerful FT-IR solution for routine compositional and quality analyses that delivers fast and accurate results with secure, cloud-connectivity. It also offers a compact footprint, advanced UATR (universal attenuated total reflectance) accessory and rugged touchscreen.

S20 Autosamplers Series - brings sample automation speed, ruggedness and versatility to labs looking to boost their productivity and cost savings, as well as future-proof their spectroscopy capabilities.

“Whether lab professionals are working to ensure the efficacy of pharmaceuticals, meeting materials regulations, aiming for zero impurities in semiconductor processes, or testing for food adulteration, they want to be more productive and collaborative and create highly reliable results and fresh insights,” said Suneet Chadha, VP/GM, Applied Markets, PerkinElmer. “Our new four quadrupole ICP-MS, FT-IR and automation solutions are designed to empower scientists and technicians to look deeper, work smarter and prepare for future needs or requirements.”

About PerkinElmer

PerkinElmer enables scientists, researchers and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise at www.perkinelmer.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SMBC and Toshiba Jointly Develop New Equity Indices Using Advanced Quantum-Driven Technologies28.5.2026 03:00:00 CEST | Press release

Sumitomo Mitsui Banking Corporation (“SMBC”) and Toshiba Corporation (“Toshiba”) today announced the joint development of the SMBC/TOSHIBA Quantum Driven Diversified Japan Equity Index and the SMBC/TOSHIBA Quantum Driven Diversified U.S. Equity Index, new equity indices realized with advanced quantum-driven technologies. Collectively, the indices are referred to as “SMBC/TOSHIBA Quantum Diversified” (the “Indices”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519448161/en/ Toshiba’s Simulated Bifurcation Machine 1. Background and Objectives Equity investment is central to asset management, but it also carries the ever-present risk of abrupt and substantial market fluctuations driven by geopolitical developments, changes in economic policy, and other external factors. In uncertain markets, investors are constantly seeking innovations in risk diversification that can protect their assets from unexpected market shocks. SM

BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 202627.5.2026 23:00:00 CEST | Press release

TEVIMBRA plus ZIIHERA and chemotherapy demonstrated statistically significant overall survival benefit with an unprecedented seven-month improvement in first-line HER2+ GEAOral presentation at ASCO highlights benefit regardless of PD-L1 status, including in PD-L1 <1% BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from HERIZON-GEA-01 were published in The New England Journal of Medicine and will be presented in an oral presentation (Rapid Oral Abstract: 4010) at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2026, in Chicago.The HERIZON-GEA-01 clinical trial evaluated ZIIHERA® (zanidatamab) plus chemotherapy, with and without TEVIMBRA® (tislelizumab), compared with the control arm of trastuzumab plus chemotherapy as first-line treatment for advanced/metastatic HER2+ gastroesophageal adenocarcinoma (GEA). Dr. Sun Young Rha, Professor of Medical Oncology at the Yonsei Cancer Center, Yonsei Univ

Stallergenes Greer Foundation Celebrates Excellence in Allergy Innovation With 2025 Awards27.5.2026 17:22:00 CEST | Press release

The Stallergenes Greer Foundation, dedicated to advancing allergy research, fostering innovation and addressing environmental factors which impact allergies, is delighted to announce the recipients of the 2025 edition of its prestigious Science Awards for Allergy. Building on the success of the previous edition, this year’s awards recognise outstanding contributions to allergy research and patient engagement and allocate a total of €100,000 to support these initiatives. Four researchers have been selected by the Board as award recipients, each receiving €25,000 across two categories: Innovation In Treatment Awards Assoc. Professor Alexander Eggel, PhD, Department for Biomedical Research, University of Bern, and Department of Rheumatology and Immunology, University Hospital Bern, Switzerland, recognised for his research: “Improving diagnostic and therapeutic options for allergic patients”; Dr Janice A. Layhadi, PhD, Research Associate, National Heart and Lung Institute, Imperial College

Capchase Secures $200M+, as Demand for Vendor Financing in Enterprise Tech Deals Accelerates27.5.2026 16:00:00 CEST | Press release

As buyers face tighter budgets, Capchase helps technology companies close more deals faster with AI-enabled instant financing Capchase, the leading vendor financing platform for enterprise tech, today announced $200M+ in incremental funding to scale its embedded financing infrastructure globally and deploy more AI-enabled features. The funding, a mix of debt warehouse facilities and equity backed by institutional investors, reflects market validation that vendor financing has become essential infrastructure for enterprise technology companies to sell hardware and software products. As global B2B buyers face tighter budgets and greater scrutiny over large, up-front purchases, financing demand is growing. The Market Shift: Financing as a Growth Lever for B2B Tech Companies The $1.3 trillion vendor financing market has been traditionally dominated by banks and other lenders that utilize multi-thread email chains to manual doc review for underwriting. Capchase replaces those bottlenecks wi

ClickHouse Tops $250M ARR and 4,000 Customers, Launches Claude-Powered Agents at Open House 202627.5.2026 15:00:00 CEST | Press release

Annual run-rate revenue more than tripled year-over-year; new CostBench benchmark shows ClickHouse Cloud at 23x better cost-performance than the nearest cloud data warehouse ClickHouse today opened Open House 2026, its second annual user conference, with a set of announcements that mark one of the company's most active quarters since founding. ClickHouse’s serverless cloud offering has crossed over $250 million in annual run-rate revenue — more than triple a year ago — and added more than 1,000 net new customers since January, bringing its total to 4,000. To meet the demands of AI-era workloads, the company also launched ClickHouse Agents, a fully managed agentic analytics service powered by Anthropic's Claude; published CostBench, an open benchmark comparing the major cloud data warehouses on cost-performance; and introduced House Mates, its first formal partner program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260527

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye